Navigation Links
NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/5/2008

with NGX- 4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements concerning future presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX

Anthony DiTonno

(650) 358-3330

aditonno@neurogesx.com

The R
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX Closes $25 Million Private Placement
2. NeurogesX, Inc. Announces $25 Million Private Placement
3. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
4. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. NeurogesX Expands Senior Management Team
6. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
7. NeurogesX Appoints New Director to the Board
8. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
9. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
10. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
11. Genta Incorporated to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Lisa Kulik saw fireworks ... July 4 holiday, thanks to a groundbreaking retinal implant ... internationally renowned clinician-researcher at the University of Southern California ... Peoria, Ariz. resident who has ... victims of sight. On June 2, she became the ...
(Date:8/27/2014)... Mass. (PRWEB) August 27, 2014 “We ... top technology vendors,” said Ven Thangaraj, CEO of Radiant ... solutions that are taking the imaging corelab market to ... sponsors, corelabs and research organizations to efficiently and effectively ... prepare the data to be analyzed and read by ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a new ... - A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds ... microelectronics to water treatment, but is graphene the ... the Graphene Opportunity Report, authored by Tim ...
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Enzyme for Pulp & Paper Industry Report 2014 2
... Nov. 16, 2010 Scientists from Chimerix, Inc. ... that the company,s lipid-conjugated drugs, CMX001 and CMX157, ... Transporters (hOATs) and thus have significantly reduced potential ... presented at the International Pharmaceutical Federation (FIP) Pharmaceutical ...
... ... ... ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... 16, 2010 Syngenta has announced the winners of ... Zoltan Balogh from Hungary and Mario Pereda from Spain ... $8000, $5000 and $3000, respectively. The winning photos were ... their quality, creativity and interpretation of Syngenta,s purpose: Bringing ...
Cached Biology Technology:Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 2Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 3Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 4Enerkem adds two new executive roles to growing North American presence 2Enerkem adds two new executive roles to growing North American presence 3Enerkem adds two new executive roles to growing North American presence 4Enerkem adds two new executive roles to growing North American presence 5Enerkem adds two new executive roles to growing North American presence 6Enerkem adds two new executive roles to growing North American presence 7Syngenta Announces Photo Prize 2010 Winners 2
(Date:8/27/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that ... of units of common stock and warrants at a ... $20 million, prior to deducting underwriting discounts and commissions ... and warrants are immediately separable and will be issued ... offering consists of 2,000 shares of common stock and ...
(Date:8/27/2014)... big step in understanding the mysteries of the human ... analyses that provide the most detailed comparison yet of ... human function. , The research, appearing August 28 ... the information encoded in the three species, genomes is ... organized into chromosomes. , The results add billions of ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 ... is available in its catalogue: Law ... http://www.reportlinker.com/p02316674/Law-Enforcement-Biometrics-Market-in-North-America-2014-2018.html About ... assess individuals on the basis of their physical ... identification of both physiological traits such as fingerprints, ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5
... mapping of the entire yeast genome in 1996 marked the ... human genome was mapped in 2001, and by now the ... are bacteria. The next advance is only a few years ... including humans. "We shall then be able to identify ...
... is available in German . , A ... already been shown in the past. Scientists at the universities ... first evidence of a shared genetic variant on chromosome 9, ... "antisense RNA" Anril, as reported in the latest edition of ...
... with dementia suffer from Alzheimer,s disease. Estimates indicate that ... Alzheimer,s patients. Alzheimer,s is a disease that gradually destroys ... of patients with Alzheimer,s gradually declines. At first, memory ... deteriorate as the disease progresses. Today, this disease cannot ...
Cached Biology News:Genetic differences between yeasts greater than those between humans and chimpanzees 2New target for medicine to combat Alzheimer's: VIB scientists confirm protein's key role 2
... meet the needs of the ... medium supports fast cell growth ... while maintaining high cell viability ... using the Baculovirus Expression Vector ...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Biology Products: